Biotech Values

[Whalatane]

AMRN

Amarin Corporation plc (NASDAQ:AMRN) today announced that the Company received a Decision to Grant from the European Patent Office (EPO) for a new patent covering VAZKEPA® (icosapent ethyl) that will extend VAZKEPA exclusivity eight additional years into 2039.
In addition, the Company recently achieved success defending a separate European VAZKEPA patent from third-party opposition within the EPO.
Collectively, these patents cover both the protocol and results from the landmark REDUCE-IT outcomes study, providing an extended and strengthened exclusivity position for VAZKEPA within the Company’s European market.
“Today’s announcement extends the commercial runway for VAZKEPA in Europe by eight additional years, which enhances the potential impact that this product can have for patients and the growth potential for VAZKEPA across the continent,” said Patrick Holt, President & CEO, Amarin. “Moving forward, we will continue to rigorously defend our IP rights and explore any possibilities to strengthen Amarin’s patents and patent families around the world.”

Gives them time to find independent confirmation of their Reduce It trial results and gain reimbursement in the major EU markets

Kiwi